Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review.
Federico J Gómez-Busto, Mario I Ortiz
Clinical neuropsychiatry December 1, 2020 DOI: 10.36131/cnfioritieditore20200606 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Peer reviewed |
|---|---|
| Keywords | Virtual reality Psychiatric disorders Hallucinogen Psychedelic |
| Citations | 12 |
| Key findings | VR is safe and effective for phobias, eating disorders, PTSD, gambling disorder, preoperative anxiety, and schizophrenia; hallucinogenic drugs show positive effects for depression, anxiety disorders, alcohol dependence, and PTSD. |
Abstract
Objective: Hallucinogenic substances or psychedelic drugs have been historically used by humans worldwide for centuries, and interest grows around them because of the therapeutic potential that they pose for mental disease. Virtual Reality (VR), has been highly developed and improved in the last decade, and it is also gaining importance due to their potential as therapeutic tools. In this article, the most recent and relevant information regarding the medical applications of both VR and psychedelics was highlighted, and diverse potential therapeutic uses were explored in hope to set the ground for further research on this topic.
Method: A systematic literature review using the PRISMA methods was conducted in PubMed, Medline, Embase, Cochrane Library, Scopus and Web of Science, including only peer-reviewed clinical trials or case studies written in English, that address the use of psychedelics and/or VR for the treatment of psychiatric disorders and that measure the success of the therapies. A final selection of 23 manuscripts were used in this systematic review.
Results: VR showed security and significant efficacy in the management of special cases of phobias (social, motion pain and spiders), eating disorder, post-traumatic stress disorder (PTSD), gambling disorder, preoperative anxiety and schizophrenia.
Conclusions: The hallucinogenic drugs evaluated exhibited positive effects in treatment of depressive and anxiety disorders, alcohol dependence and PTSD. More research is needed in order to test the effectiveness of these therapies (alone or together) in different mental illnesses and different populations.
Citations in the library
Cited by 5
- Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study. Frontiers in Psychiatry March 1, 2023
- Cyberdelics in context: On the prospects and challenges of mind-manifesting technologies. Frontiers in Psychology 2022
- What should constitute a control condition in psychedelic drug trials? Nature Mental Health October 1, 2024
- Therapeutic dissociation: From non-ordinary states to psychological transformation January 12, 2024
- The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic Review Journal of Sociology, Psychology & Religious Studies November 6, 2023
Cites 28
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- Global Street Food: la cocina de la calle Diseño interior 2009
and 23 more in the library